Play all audios:
![Access through your institution Buy or subscribe Martini A., Touzani A., Mazzone E., Roumiguié M., Marra G., Valerio M., et al. state that the use of targeted biopsies has recently been under scrutiny [1]. In our opinion, the analysis, and the conclusion of limited downgrading from multiparametric MRI biopsies to radical prostatectomy (RP) specimen does not change that [1]. It is interesting to study the grade and stage migration, however, this has nothing to do with evaluating the risk of overdiagnosis. The authors show that ISUP 2 histological grade obtained by multiparametric MRI biopsies targeted to the cancerous lesion is seldomly downgraded when compared with the RP specimen and suggest that MRI targeting does not lead to overdiagnosis [1]. Overdiagnosis is a term used to describe men who are diagnosed with a disease that will never develop into symptoms or death, which is not reported here. Moreover, some aspects of the article need of clarification. The authors state that the men included had no prior biopsies, however, in the Table, 210 men are reported with one or more prior biopsies. Furthermore, among the men with ISUP 2 on RP pathology, 60% is reported as pT0, indicating no cancer found in the specimen, and an additional 32% is reported with pT1, both findings need clarification. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and online access $259.00 per year only $64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Martini A, Touzani A, Mazzone E, Roumiguié M, Marra G, Valerio M, et al. Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions. Prostate Cancer Prostatic Dis. 2022. https://doi.org/10.1038/s41391-022-00606-6. * Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl J Med. 2016;375:1415–24. Article PubMed Google Scholar * Boesen L, Nørgaard N, Løgager V, Balslev I, Bisbjerg R, Thestrup KC, et al. Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7–10 prostate cancer in biopsy-naïve men. Eur Urol Oncol. 2019; 2. https://doi.org/10.1016/j.euo.2018.09.001. * Kawa SM, Stroomberg HV, Larsen SB, Helgstrand JT, Toft BG, Vickers AJ, et al. A nationwide analysis of risk of prostate cancer diagnosis and mortality following an initial negative TRUS-biopsy with long-term follow-up. J Urol. 2022;208:100–8. Article PubMed PubMed Central Google Scholar * Hilscher M, Røder A, Helgstrand JT, Klemann N, Brasso K, Vickers AJ, et al. Risk of prostate cancer and death after benign transurethral resection of the prostate—A 20‐year population‐based analysis. Cancer. 2022;128:3674–3680. Article PubMed Google Scholar Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Copenhagen Prostate Cancer Center, Department of Urology, Center for Cancer and Organ Disease - Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark Hein Vincent Stroomberg, Klaus Brasso & Andreas Røder * Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark Hein Vincent Stroomberg * Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark Klaus Brasso & Andreas Røder Authors * Hein Vincent Stroomberg View author publications You can also search for this author inPubMed Google Scholar * Klaus Brasso View author publications You can also search for this author inPubMed Google Scholar * Andreas Røder View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS Conceptualization: HVS, KB, AR; Writing – Original Draft: HVS; Writing – Review & Editing: HVS, KB, AR. CORRESPONDING AUTHOR Correspondence to Hein Vincent Stroomberg. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Stroomberg, H.V., Brasso, K. & Røder, A. Fact, overdiagnosis cannot be evaluated by comparing histological grading of prostate biopsy to prostatectomy specimen. _Prostate Cancer Prostatic Dis_ 26, 804–805 (2023). https://doi.org/10.1038/s41391-022-00629-z Download citation * Received: 11 November 2022 * Revised: 28 November 2022 * Accepted: 30 November 2022 * Published: 09 December 2022 * Issue Date: December 2023 * DOI: https://doi.org/10.1038/s41391-022-00629-z SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative](data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>)
Access through your institution Buy or subscribe Martini A., Touzani A., Mazzone E., Roumiguié M., Marra G., Valerio M., et al. state that the use of targeted biopsies has recently been
under scrutiny [1]. In our opinion, the analysis, and the conclusion of limited downgrading from multiparametric MRI biopsies to radical prostatectomy (RP) specimen does not change that [1].
It is interesting to study the grade and stage migration, however, this has nothing to do with evaluating the risk of overdiagnosis. The authors show that ISUP 2 histological grade obtained
by multiparametric MRI biopsies targeted to the cancerous lesion is seldomly downgraded when compared with the RP specimen and suggest that MRI targeting does not lead to overdiagnosis [1].
Overdiagnosis is a term used to describe men who are diagnosed with a disease that will never develop into symptoms or death, which is not reported here. Moreover, some aspects of the
article need of clarification. The authors state that the men included had no prior biopsies, however, in the Table, 210 men are reported with one or more prior biopsies. Furthermore, among
the men with ISUP 2 on RP pathology, 60% is reported as pT0, indicating no cancer found in the specimen, and an additional 32% is reported with pT1, both findings need clarification. This is
a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and online access $259.00 per
year only $64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated
during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Martini A, Touzani A, Mazzone E,
Roumiguié M, Marra G, Valerio M, et al. Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions. Prostate Cancer Prostatic Dis. 2022.
https://doi.org/10.1038/s41391-022-00606-6. * Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized
prostate cancer. N. Engl J Med. 2016;375:1415–24. Article PubMed Google Scholar * Boesen L, Nørgaard N, Løgager V, Balslev I, Bisbjerg R, Thestrup KC, et al. Prebiopsy biparametric
magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7–10 prostate cancer in biopsy-naïve men. Eur Urol Oncol. 2019; 2.
https://doi.org/10.1016/j.euo.2018.09.001. * Kawa SM, Stroomberg HV, Larsen SB, Helgstrand JT, Toft BG, Vickers AJ, et al. A nationwide analysis of risk of prostate cancer diagnosis and
mortality following an initial negative TRUS-biopsy with long-term follow-up. J Urol. 2022;208:100–8. Article PubMed PubMed Central Google Scholar * Hilscher M, Røder A, Helgstrand JT,
Klemann N, Brasso K, Vickers AJ, et al. Risk of prostate cancer and death after benign transurethral resection of the prostate—A 20‐year population‐based analysis. Cancer.
2022;128:3674–3680. Article PubMed Google Scholar Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Copenhagen Prostate Cancer Center, Department of Urology, Center for
Cancer and Organ Disease - Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark Hein Vincent Stroomberg, Klaus Brasso & Andreas Røder * Department of Public Health,
Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark Hein Vincent Stroomberg * Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark Klaus Brasso
& Andreas Røder Authors * Hein Vincent Stroomberg View author publications You can also search for this author inPubMed Google Scholar * Klaus Brasso View author publications You can
also search for this author inPubMed Google Scholar * Andreas Røder View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS Conceptualization: HVS,
KB, AR; Writing – Original Draft: HVS; Writing – Review & Editing: HVS, KB, AR. CORRESPONDING AUTHOR Correspondence to Hein Vincent Stroomberg. ETHICS DECLARATIONS COMPETING INTERESTS
The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional
affiliations. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Stroomberg, H.V., Brasso, K. & Røder, A. Fact, overdiagnosis cannot be evaluated by
comparing histological grading of prostate biopsy to prostatectomy specimen. _Prostate Cancer Prostatic Dis_ 26, 804–805 (2023). https://doi.org/10.1038/s41391-022-00629-z Download citation
* Received: 11 November 2022 * Revised: 28 November 2022 * Accepted: 30 November 2022 * Published: 09 December 2022 * Issue Date: December 2023 * DOI:
https://doi.org/10.1038/s41391-022-00629-z SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not
currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative